The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
about
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipationTreatment for constipation: new and old pharmacological strategiesEvaluation and management of dyspepsia.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersBasic and clinical pharmacology of new motility promoting agents.Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair.Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet.The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development.A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors.Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity.The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.A hybrid structural approach to analyze ligand binding by the serotonin type 4 receptor (5-HT4).Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity.Serotonin and neuroprotection in functional bowel disorders.Development of drugs for gastrointestinal motor disorders: translating science to clinical need.Choledochoscope manometry about different drugs on the Sphincter of Oddi.Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in ratsNew-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.Behavioural and new pharmacological treatments for constipation: getting the balance rightInvestigational agents for the irritable bowel syndrome.Existing and emerging therapies for irritable bowel syndrome.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology.5-HTR3 and 5-HTR4 located on the mitochondrial membrane and functionally regulated mitochondrial functions.Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro.Divergent changes to muscarinic and serotonergic signalling following colitis.Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation.Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod.Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension.Neurogastroenterology of tegaserod (HTF 919) in the submucosal division of the guinea-pig and human enteric nervous system.Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers.Effect of the 5-HT4 receptor agonist tegaserod on the expression of GRK2 and GRK6 in the rat gastrointestinal tract.
P2860
Q24607588-A307CAE7-5DBB-48A3-A092-EC635D99A2FBQ27027346-23D80D4C-89B2-40AC-A31D-E67018370270Q30433839-F3E8A504-3C21-452A-9B06-4D7A290426F8Q30486707-B473960A-39B8-4C55-9C0C-C0C05C9FF5DBQ30490465-6134E9FD-8FF2-4705-AF9F-85865E4255F7Q34166903-37ED1FB5-6BFA-45C7-8ECE-8192FE93529EQ34453951-5D10F657-EDE2-4615-9777-FA0D4024FC0BQ34997967-DFB52F6B-6D27-47E7-8A16-31BFF603BDBFQ35021543-AAD40CE5-5964-4EDC-8B85-18B48A461748Q35025872-D159987C-0887-4717-B108-F14A7046B014Q35098633-9EA815C6-E444-4403-91CE-ECBA3B0B1987Q36052511-CF2DE0E9-FE77-4E90-95A1-198FE79C1390Q36336675-0B680582-10F7-412C-9F8E-14F305C61DBFQ36407290-E0D9F2DB-7E64-4827-AB94-DC80FE7E5190Q36728938-91645A45-57FA-4F08-B2F9-2267E8AC0D05Q36832484-0E7B138E-11B3-44D2-AC6B-AE4680A98D92Q36874377-3F4E3CE1-15E8-4BAF-9FDB-936F0576F5FBQ36874381-899424F4-A394-4676-A383-EEDAD9A13AD9Q37079261-DE005139-D7D3-49C2-8AE0-30E3C7A9BF6AQ37362716-00D62576-43E0-46BB-B643-BB4B1EC91243Q37434409-853D9FB9-BCDB-4CD4-AF57-F2B62B7C1980Q37735172-718E47FD-B5B9-4CB4-9C8C-3CEF1862295AQ37783838-99D8A0BC-F93C-4E94-9994-D550441A9FB6Q37788218-3134E35C-202A-4AF9-8C36-82C986047B3AQ37857849-07D78154-B27A-4514-9D61-EBAB0D883E13Q37954521-36F064F8-21D5-4E2C-80C7-DEAD6B050C31Q37960501-A2377743-CC71-4873-82D4-0B01B9FCF65FQ38178543-0EF5676B-4185-407D-8C61-5257B9A3CDEFQ38648544-7B3BE92E-3248-4583-8CCF-42F3384BA97EQ39334996-24132CEE-A1E7-4AB3-B5C4-E01477858964Q39860291-B287F9F9-A4FA-42A3-BB79-286F18D0C43AQ41895270-8F28D987-76C4-4A54-B51A-6D7182707529Q41952109-F7430311-61E3-43E0-AB4A-6FEF1D02B58CQ42221667-9BCB070F-BC84-40BD-B657-2F968B0BD460Q42703872-0D8BC501-54D7-4671-8542-626496D894A9Q44914306-BD9458D9-9950-4E37-ACC2-82A500A7C36DQ46863112-B899499B-F446-4582-B003-B70DE38ECE64Q46921555-A1DE35AD-56D2-4BB6-86E2-1AB8F8B8C3C2Q51491947-16E51249-9C26-4395-A644-8CC6A5D2D683Q55288044-3D54CAEC-CDBF-43CE-90E0-4CFA590CE9E5
P2860
The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@ast
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@en
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@nl
type
label
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@ast
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@en
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@nl
prefLabel
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@ast
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@en
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@nl
P2093
P2860
P356
P1476
The 5-HT4 receptor agonist, te ...... ntagonist in vitro and in vivo
@en
P2093
C Richardson
C Sandlund
D Marquess
D T Beattie
J A M Smith
J L McCullough
P P A Humphrey
R G Vickery
S R Armstrong
P2860
P304
P356
10.1038/SJ.BJP.0705929
P407
P577
2004-11-01T00:00:00Z